BACKGROUND: Obesity is associated with poor outcomes in many diseases, although recent data suggest that acute lung injury (ALI) is an exception. This is particularly interesting because obesity is marked by increased levels of proinflammatory mediators associated with increased morbidity and mortality in ALI. We hypothesized that cytokine response might be attenuated in patients who are obese and critically ill or that obesity might modify the relationship between plasma cytokines and clinical outcomes in ALI. METHODS: We analyzed plasma biomarker levels (interleukin [IL]-6, IL-8, tumor necrosis factor-alpha receptor 1, surfactant protein D [SP-D], soluble intracellular adhesion molecule, von Willebrand factor (vWF), protein C, and plasminogen activator inhibitor-1) collected at baseline and day 3 in 1,409 participants in prior National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network (ARDSNet) trials. BMI was calculated for each patient, and associations with cytokine levels and ventilator-free days (VFDs), organ failure-free days (OFDs), and mortality were investigated in regression models adjusting for confounders. RESULTS: In adjusted analyses, plasma IL-6 (P = .052), IL-8 (P = .001), and SP-D (P < .001) were inversely related to BMI, whereas vWF (P = .001) and WBC count (P = .042) increased proportionally with BMI. BMI was not associated with increased morbidity or mortality and did not modify the association between baseline biomarker levels and mortality, VFDs, or OFDs. CONCLUSIONS: Patients who are obese and have ALI have lower levels of several proinflammatory cytokines, suggesting that the inflammatory response may be altered in patients with ALI and a high BMI. Lower SP-D but higher vWF suggests decreased epithelial and increased endothelial injury in the lung of patients who are obese. Mechanisms by which obesity may modulate innate immunity in critical illness are unclear, and future studies should elucidate such mechanisms.
RCT Entities:
BACKGROUND:Obesity is associated with poor outcomes in many diseases, although recent data suggest that acute lung injury (ALI) is an exception. This is particularly interesting because obesity is marked by increased levels of proinflammatory mediators associated with increased morbidity and mortality in ALI. We hypothesized that cytokine response might be attenuated in patients who are obese and critically ill or that obesity might modify the relationship between plasma cytokines and clinical outcomes in ALI. METHODS: We analyzed plasma biomarker levels (interleukin [IL]-6, IL-8, tumor necrosis factor-alpha receptor 1, surfactant protein D [SP-D], soluble intracellular adhesion molecule, von Willebrand factor (vWF), protein C, and plasminogen activator inhibitor-1) collected at baseline and day 3 in 1,409 participants in prior National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network (ARDSNet) trials. BMI was calculated for each patient, and associations with cytokine levels and ventilator-free days (VFDs), organ failure-free days (OFDs), and mortality were investigated in regression models adjusting for confounders. RESULTS: In adjusted analyses, plasma IL-6 (P = .052), IL-8 (P = .001), and SP-D (P < .001) were inversely related to BMI, whereas vWF (P = .001) and WBC count (P = .042) increased proportionally with BMI. BMI was not associated with increased morbidity or mortality and did not modify the association between baseline biomarker levels and mortality, VFDs, or OFDs. CONCLUSIONS:Patients who are obese and have ALI have lower levels of several proinflammatory cytokines, suggesting that the inflammatory response may be altered in patients with ALI and a high BMI. Lower SP-D but higher vWF suggests decreased epithelial and increased endothelial injury in the lung of patients who are obese. Mechanisms by which obesity may modulate innate immunity in critical illness are unclear, and future studies should elucidate such mechanisms.
Authors: Polly E Parsons; Michael A Matthay; Lorraine B Ware; Mark D Eisner Journal: Am J Physiol Lung Cell Mol Physiol Date: 2004-10-29 Impact factor: 5.464
Authors: Y H Lee; S Nair; E Rousseau; D B Allison; G P Page; P A Tataranni; C Bogardus; P A Permana Journal: Diabetologia Date: 2005-07-30 Impact factor: 10.122
Authors: Polly E Parsons; Mark D Eisner; B Taylor Thompson; Michael A Matthay; Marek Ancukiewicz; Gordon R Bernard; Arthur P Wheeler Journal: Crit Care Med Date: 2005-01 Impact factor: 7.598
Authors: James M O'Brien; Gary S Phillips; Naeem A Ali; Maria Lucarelli; Clay B Marsh; Stanley Lemeshow Journal: Crit Care Med Date: 2006-03 Impact factor: 7.598
Authors: Shan L Ward; Virginia Gildengorin; Stacey L Valentine; Anil Sapru; Martha A Q Curley; Neal Thomas; Douglas F Willson; Heidi R Flori Journal: Crit Care Med Date: 2016-11 Impact factor: 7.598
Authors: Jenny L Martino; Renee D Stapleton; Miao Wang; Andrew G Day; Naomi E Cahill; Anne E Dixon; Benjamin T Suratt; Daren K Heyland Journal: Chest Date: 2011-08-04 Impact factor: 9.410
Authors: Carolyn M Hendrickson; Jason Abbott; Hanjing Zhuo; Kathleen D Liu; Carolyn S Calfee; Michael A Matthay Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-02-17 Impact factor: 5.464
Authors: Lauren L Kordonowy; Elianne Burg; Christopher C Lenox; Lauren M Gauthier; Joseph M Petty; Maryellen Antkowiak; Tatsiana Palvinskaya; Niki Ubags; Mercedes Rincón; Anne E Dixon; Juanita H J Vernooy; Michael B Fessler; Matthew E Poynter; Benjamin T Suratt Journal: Am J Respir Cell Mol Biol Date: 2012-03-15 Impact factor: 6.914
Authors: Michael R Wilson; Joanne E Petrie; Michael W Shaw; Cong Hu; Charlotte M Oakley; Samantha J Woods; Brijesh V Patel; Kieran P O'Dea; Masao Takata Journal: Crit Care Med Date: 2017-08 Impact factor: 7.598
Authors: Michael G S Shashaty; Esra Kalkan; Scarlett L Bellamy; John P Reilly; Daniel N Holena; Kathleen Cummins; Paul N Lanken; Harold I Feldman; Muredach P Reilly; Jayaram K Udupa; Jason D Christie Journal: Crit Care Med Date: 2014-07 Impact factor: 7.598